Abstract 2156
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. After breast cancer surgery, the patients are generally preferred to have verbal expressions in their education. In this context, it is considered that mobile application is the right choice in order to provide the opportunity for the patients to manage their post-operative processes, to facilitate their access to the right information and to provide a positive contribution to their quality of life by providing consultancy services.
Methods
The text content of the mobile application has text, image, video and audio equipment as well as online support / consulting services. It is thought that the mobile application will have a separate interface for each problem, and text and animation content will be the only problem for each interface. Care was taken to ensure that the created interfaces were of different colors and the layout to be used for problem solving was similar for each interface. It was ensured that the patients were checked from the admin panel if they did not watch or watch the videos again. All these operations were entered by entering the user name and password and recorded by end-to-end encryption.
Results
Supporting self-care for a woman who has not yet achieved her responsibility to cope with all responsibilities will contribute to the maintenance of family unity. In the creation of a mobile application that can be reached continuously; It is aimed to support self-care, create a tool that can receive support without any social isolation, decrease individual dependence and increase self-esteem. Thus, the fact that the woman does not have to spend the post-operative period at home and can be used individually and at the desired time constitutes the other advantages of the mobile application.
Conclusions
If the patient with breast surgery has an equipment to support self-care in the post-operative home, it will be possible to decrease the rate of experiencing physiological, psychological and sociological problems. It will be possible for the patient who has no problems to decrease their applications to the hospital and to contribute to the economy of the country.
Clinical trial identification
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract